Atrial Fibrillation (AF) is an irregular heartbeat caused by erratic electrical activity in the upper heart chambers. AF patients, numbering over 33 million worldwide and growing annually by 5%, have 5x the risk of stroke and 3x the risk of heart failure. While current management in the U.S. alone costs $26 billion, current treatments are mired by high reoccurrence rates and debilitation of heart tissue.

SaluTech is developing a proprietary conductive biomaterial (CBM) to treat patients suffering from AF, by addressing the underlying electrophysiological causes of AF to restore a healthy heartbeat. CBM is a non-toxic, long-lasting, and biocompatible nano-membrane that is able to mimic the conductive velocity of healthy heart tissue. In coating the atria with our CBM membrane, CBM not only effectively treats AF, but also works to improve overall heart function in AF patients.

The patent-protected technology was originally developed within the University Health Network in Toronto, Canada. SaluTech is currently completing large animal studies, and looking to move forward to clinical trials.